Virtually all commercial Intervertebral Disc Replacement Therapies (IDTR) have a ball and socket design concept. These designs cannot mimic the viscoelastic and shock absorbent capacity of the natural disc.
Current strategies for disc replacement do not allow for natural spinal motions and offer only partly relieve of complaints or introduce new limitations. By using a biomimetic replacement for the disk, the patient outcomes would improve.
The global Total Cervical Disc Replacement Market alone is valued at EUR 1 billion and is rapidly growing. In addition, Mimesis Spine will offer solutions for partial disc repair and for the lumbar spine.
There is a significant need to improve patient outcomes and quality of life, as well as save medical costs by addressing the degradation process earlier that is currently done.
Mimesis Spine is developing a treatment platform that matches the cascade of degeneration of the spine, offering different treatments depending on the stage degeneration in the cervical or lumbar region. This will allow surgeons to perform hybrid procedures constructs where they offer a different solution on a spinal motion segment basis.
The main product will be the CTDR (Cervical Total Disc Replacement). An ingenious combination of hydrogels and scaffolds, which is applied dependent on the severity of degeneration, can prevent stiffening and improve range of motion.
A patent for the technology has been filed. Memesis Spine is at TRL2 and currently developing its first prototype for preclinical testing
Meet the team
Gina joined NLC in February 2020. Previously, Gina worked in Venture Capital at Biogeneration Ventures and in Strategy Consulting at Oliver Wyman. Her academic background includes a Masters degree in Biotechnology from ETH Zurich. At NLC, Gina is the responsible Venture Partner for multiple Medtech and Biotech ventures and also leads the Medtech Domain within NLC’s Venture Creation engine.